ChartSpan raises $1.7M for mobile PHR, aims to launch paid analytics tool this year From Mobil Health News

by Admin on February 27, 2015 · 0 comments

in Mobil health

Greenville, South Carolina-based ChartSpan has raised $1.7 million in a round led by existing investor, Byrne Medical’s Don Byrne. This brings the company’s total funding to just under $3 million. The Iron Yard, a digital health accelerator that incubated ChartSpan, contributed to ChartSpan’s previous round. The company offers patients a personal health record (PHR) tool, which, as […]

from mobihealthnews http://ift.tt/1ASoc9K
via IFTTT

Tagged as: ,

{ 0 comments }

How can health wearables reach health app adoption levels? From Mobil Health News

by Admin on February 27, 2015 · 0 comments

in Mobil health

The ePharma Summit in New York City this week was a veritable smorgasbord of new mobile health data. Monique Levy shared some new data (and insights) from Manhattan Research, Tom Jones from Makovsky Health shared data about consumer mobile health use, and, finally, ComScore’s John Mangano shared data from a survey of 2,929 individuals, broken […]

from mobihealthnews http://ift.tt/1DAFJ7s
via IFTTT

Tagged as: ,

{ 0 comments }

Report: Fitbit mulling an acquisition of FitStar, a fitness coaching app startup From Mobil Health News

by Admin 02.27.2015

Fitbit is in discussions to acquire fitness coaching app developer, FitStar, for $25 to $40 million in a mix of cash and stock as early as next week, according to a report from TechCrunch. The report adds that it’s possible the deal may not go through. FitStar has created two apps, FitStar Personal Trainer and FitStar Yoga. […]

0 comments Read the rest

In-Depth: Anticipating FDA Regulation of Pharmaceutical Apps From Mobil Health News

by Admin 02.27.2015

By Bradley Merrill Thompson Over the last couple years, FDA has clarified the scope of its regulation over mobile health. In the agency’s September 2013 guidance, FDA spelled out its oversight for some of the most common mobile medical apps. Then, last month, in two separate draft guidances FDA explained the limits on its oversight […]

0 comments Read the rest

← Previous Entries